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Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate
definition was developed to distinguish luminal A–like breast cancer from luminal B–like disease based on a
combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for
molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement
for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes
in terms of distant disease control in a large series of patients.
Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal
growth factor receptor 2 (HER2)–negative early breast cancer and (2) had undergone surgery at the European Institute of
Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with “low” (<14%), “intermediate”
(14% to 19%) or “high” (≥20%) Ki-67 positivity stratified by PgR expression (negative or low versus high). We calculated
the cumulative incidence of distant events, considered competing events and performed multivariable analysis adjusted
for pathologic tumor stage, pathologic node stage, tumor grade, peritumoral vascular invasion and menopausal status.
Results: Lack of substantial PgR positivity was associated with poorer outcomes only for patients with an
intermediate Ki-67 level (P < 0.001). The 4,890 patients (51.9%) with low Ki-67 level (any PgR expression level) or
with intermediate Ki-67 level but substantial PgR positivity had comparably good outcomes and thus may
represent a most advantageous grouping of those with luminal A–like disease.
Conclusions: The updated pathological definition of intrinsic molecular subtypes may maximize the number of
patients classified as having the luminal A–like intrinsic subtype of breast cancer and for whom the use of
cytotoxic drugs could mostly be avoided.Introduction
At the 13th St Gallen International Breast Cancer Con-
ference in 2013, an international expert panel reviewed
the clinicopathological surrogate definitions of breast
cancer subtypes [1]. On the basis particularly of results
of the Prat et al. study [2], the panel advised that the
clarity of the distinction between “luminal A–like” and* Correspondence: patrick.maisonneuve@ieo.it
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article, unless otherwise stated.“luminal B–like” tumors could be improved from the pre-
vious consensus guidelines [3] by including a requirement
for substantial progesterone receptor (PgR) positivity
(≥20%) in the definition of “luminal A–like” disease.
As described in the expert consensus report, adding this
restriction will have the effect of reducing the number of
patients classified as having luminal A–like cancer and
thus increase the number for whom cytotoxic therapy is
generally recommended. Concurrently, the expert panel
removed the threshold value for “high Ki-67” in the sur-
rogate definition of the luminal B subtype. A level ofentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of luminal A and luminal B intrinsic subtypes, but, on
the basis of a comparison in which gene array data were
utilized [4], a majority of the panel voted that a threshold
of ≥20% is indicative of high Ki-67 status [1]. Although
not explicitly recommended, application of this new cut
point will have the opposite effect of increasing the num-
ber of patients classified as having luminal A–like breast
cancer and thus decreasing the number for whom cyto-
toxic therapy is generally recommended.
In order to verify the suitability of the new surrogate
definitions of intrinsic breast cancer subtypes, we re-
trieved information on a large series of women treated
for a first primary nonmetastatic breast cancer at the
European Institute of Oncology (IEO) (Milan, Italy) be-
tween 1994 and 2006 and compared their outcomes ac-
cording to the surrogate definitions of intrinsic subtypes
proposed at the 12th St Gallen International Breast Cancer
Conference and also according to the revised definition
proposed at the 13th conference [1].
Methods
Study population
The initial data set used for this analysis comprised all
women who had undergone surgery for a first primary
breast cancer at the IEO between 1994 and 2006 and
had not received neoadjuvant treatment. Data were pro-
spectively collected from the institutional breast cancer
database. Women with metastatic breast disease at the
time of presentation or established within 3 months after
surgery were excluded. For 1,207 (9.1%) of the 13,265 re-
maining patients, assessment of human epidermal growth
factor receptor 2 (HER2) status was missing, thus im-
peding the determination of intrinsic molecular tumor
subtypes. For the purposes of the study, an additional
1,669 patients (12.6%) with HER2-positive tumors (1,008
endocrine-responsive and 661 endocrine-nonresponsive)
and 974 patients (7.3%) with triple-negative tumors were
also excluded, because no modifications were made in
the revised consensus for the definitions of the “luminal
B (HER2-positive)”, “HER2-positive” or “triple-negative”
breast cancer subtypes. The final data set comprises 9,415
patients with endocrine-responsive, HER2-negative breast
cancer.
Our use of the data was approved by the ethics com-
mittee of the IEO and by the Italian Data Protection Au-
thority (Garante per la protezione dei dati personali),
and the need for individual patients’ consent was waived.
Laboratory methods
Tumors were classified histologically according to the
World Health Organization’s histological classification
system as modified by Rosen and Obermann [5]. Tumor
grade was evaluated according to the classification schemedescribed by Elston and Ellis [6]. Immunohistochemical
staining for estrogen receptor (ER), PgR, HER2 protein
and Ki-67 antigen was performed with consecutive tis-
sue sections from the same tumor blocks. The following
primary antibodies were used: the monoclonal antibody
(mAb) against ER (clone 1D5, 1:100 dilution; Dako,
Glostrup, Denmark), the mAb against PgR (clone 1A6,
1:800 dilution; Dako), the MIB-1 mAb against Ki-67
antigen (1:100 dilution; Dako) and the polyclonal anti-
body against HER2 protein (1:3,200 dilution; Dako).
Only nuclear reactivity was taken into account for ER,
PgR and Ki-67, irrespective of the staining intensity,
whereas only intense and complete membrane staining
in >10% of the tumor cells were considered HER2 over-
expression (3+). In addition, fluorescence in situ hybridiza-
tion assays were performed for the final determination of
HER2 status for tumors with 2+ immunoreactivity.
Follow-up and outcomes
Patients were followed for recurrence or death according to
clinical protocols. For those no longer attending clinical
visits at our institute, essential follow-up information was
collected by telephone. For those lost to follow-up, informa-
tion on vital status was obtained from the municipal vital
statistics office. For the purposes of this report, the main
outcome was distant disease-free survival (DDFS), taking
into consideration development of metastasis in distant
organs and death due to breast cancer as primary events.
Statistical analysis
Associations between categorical and ordinal variables
and PgR or Ki-67 status were evaluated with the χ2 test.
DDFS duration was calculated from the date of surgery
until the date of any first event or the date of last con-
tact with the patient. Curves of the cumulative incidence
of events were drawn considering metastases and deaths
due to breast cancer as events and locoregional events,
contralateral tumors, nonbreast primary tumors and deaths
due to other or unknown causes considered as competing
events. Cumulative incidences were compared across dif-
ferent subgroups by means of the Gray test. Multivariable
Cox proportional hazards models were used to evaluate
risk of metastasis or death due to breast cancer across
groups, adjusting for pathologic tumor stage (pT), patho-
logic node stage (pN), tumor grade, peritumoral vascular
invasion and menopausal status. All analyses were carried
out with SAS software (version 9.3; SAS Institute, Cary,
NC, USA). All P-values are two-sided.
Results
The characteristics of the 9,415 patients who had surgery
for endocrine-responsive, HER2-negative breast cancer
and who satisfied the eligibility criteria are described in
Table 1 and Additional file 1: Table S1. Among those
Table 1 Characteristics of the patientsa
Variables Number of patients (%)
All 9,415 (100)
Age at surgery, yr
<35 309 (3.3)
35 to 50 3,809 (40.5)
51 to 65 3,637 (38.6)
>65 1,660 (17.6)
Menopausal status
Premenopausal 4,278 (45.4)
Postmenopausal 5,137 (54.6)
Histological tumor subtype
Ductal 7,114 (75.6)
Lobular 1,150 (12.2)
Mixed 397 (4.2)
Other 754 (8.0)
pT
pT1 6,601 (70.1)
pT2 2,514 (26.7)
pT3/4 300 (3.2)
pN
pNx 309 (3.3)
pN0 5,201 (55.2)
pN+ 3,905 (41.5)
Tumor grade
G1 2,160 (22.9)
G2 4,930 (52.4)
G3 2,007 (21.3)
NA 318 (3.4)
ER positivity
≥20% 9,228 (98.0)
<20% 187 (2.0)
PgR positivity
≥20% 6,758 (71.8)
<20% 2,657 (28.2)
Ki-67 level
<14% 3,169 (33.7)
14% to 19% 2,276 (24.2)
≥20% 3,970 (42.2)
PVI
Absent 7,039 (74.8)
Present 2,376 (25.2)
Surgery
Quadrantectomy 7,777 (82.6)
Mastectomy 1,638 (17.4)
Table 1 Characteristics of the patientsa (Continued)
Radiotherapy
No 1,416 (15.0)
Yes 7,999 (85.0)
Chemotherapy
No 6,386 (67.8)
Yes 3,029 (32.2)
Competing riskb
No events 7,149 (75.9)
Locoregional relapse 592 (6.3)
Distant metastasis 852 (9.0)
Other 822 (8.7)
aER, Estrogen receptor; NA, Not applicable; PgR, Progesterone receptor; pN,
Pathologic node stage; pT, Pathologic tumor stage; PVI, Peritumoral vascular
invasion. bDuring a median follow-up time, estimated in nonevents, of 8.1 years
(IQR = 6.1 to 10.2 years).
Maisonneuve et al. Breast Cancer Research 2014, 16:R65 Page 3 of 9
http://breast-cancer-research.com/content/16/3/R65patients, 4,278 (45.4%) were in premenopause. The tu-
mors were ductal in 7,114 cases (75.6%), lobular in 1,150
cases (12.2%), mixed ductal and lobular in 397 cases
(4.2%) and of other histological subtype in the remaining
754 cases (8.0%). A total of 6,601 (70.1%) of the patients
had pT1 disease, and 5,510 patients (58.5%) had no re-
gional lymph node involvement (pNx/or pN0). A total of
7,777 (82.6%) of the women had undergone breast-
conserving surgery, 7,999 (85.0%) had received adjuvant
radiotherapy and 3,029 (32.2%) had been treated with ad-
juvant chemotherapy. During a median follow-up of
8.1 years (IQR = 6.1 to 10.2 years), 592 women (6.3%) had
a locoregional relapse, 852 (9.0%) developed a distant me-
tastasis and 822 (8.7%) had some other event (contralat-
eral breast cancer, other primary or death) (Table 1).
Totals of 3,169 (33.7%) of the patients had luminal A–
like breast cancer and 6,246 (66.3%) had luminal B–like
breast cancer on the basis of the initial surrogate defin-
ition of intrinsic molecular subtypes proposed by the
international expert consensus panel in 2011 (Figure 1).
When we applied the 2013 updated St Gallen definition
of intrinsic subtypes, we found that 854 (26.9%) of the
3,169 tumors previously classified as luminal A–like were
now luminal B–like tumors because they were associated
with negative or low PgR levels. Conversely, 1,721 (75.6%)
of the 2,276 initially luminal B–like tumors associated
with intermediate Ki-67 levels (that is, between 14% and
20%) had PgR expression levels ≥20% and thus were re-
classified as luminal A–like tumors. As a result, 4,036
(42.9%) of the patients were reclassified as having luminal
A–like disease and 5,379 (57.1%) were considered to have
luminal B–like breast cancer (Figure 1).
In order to verify whether the single modifications im-
proved the categorization of patients in terms of out-
comes, we evaluated the long-term DDFS of patients with
low (<14%), intermediate (14% to 19%) and high (≥20%)
Figure 1 Patient distribution according to molecular characteristics and St Gallen 2011 and 2013 intrinsic molecular subtype
definitions. The threshold of ≥14% for Ki-67 in the 2011 definition was derived from comparison with gene array data as a prognostic factor
[3,4], whereas the threshold of ≥20% in the 2013 definition was approved by the majority of the expert consensus panel [1]. HER2, Human
epidermal growth factor receptor 2; PgR, Progesterone receptor.
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vs. ≥20%) (Figure 2).
The DDFS durations of the 854 women with low
Ki-67 expression and low PgR levels (that is, those
who were reclassified as having luminal B–like ins-
tead of luminal A–like breast cancer according to the
2013 definitions) were similar to those of the 2,315
women with low Ki-67 expression and high PgR levels
(that is, those who remained classified as having luminal
A–like breast cancer) (hazard ratio (HR) = 1.05, 95%Figure 2 Distant disease-free survival according to Ki-67 and progest
(<14%). (b) Patients with intermediate Ki-67 expression (14% to 19%). (c) P
10-year cumulative incidence. (e) Multivariable analysis. PgR, Progesterone
calculated using a multivariable Cox proportional hazards regression mode
grade, peritumoral vascular invasion and menopausal status.confidence interval (CI) = 0.67 to 1.65; P = 0.80 by Gray
test) (Figure 2a).
The DDFS durations of the 1,721 women with inter-
mediate Ki-67 expression and high PgR levels (that is,
those who were reclassified as having luminal A–like in-
stead of luminal B–like breast cancer according to the
2013 definitions) were significantly better than those of
the remaining 555 women with intermediate Ki-67 ex-
pression and low PgR levels (HR = 1.86, 95% CI = 1.37 to
2.52; P < 0.001 by Gray test) (Figure 2b).erone receptor expression levels. (a) Patients with low Ki-67 levels
atients with high Ki-67 expression (≥20%). (d) Number of patients and
receptor. Hazard ratios (HRs) and 95% confidence intervals (CIs) were
l adjusted for pathologic tumor stage, pathologic node stage, tumor
Table 2 New proposal for surrogate definitions of
intrinsic subtypes of HER2-negative, endocrine-
responsive breast cancera
Intrinsic subtypes Clinicopathological surrogate definitions
Luminal A “Luminal A–like”
All of:
ER-positive
HER2-negative
And at least one of:
Ki-67 low expression (<14%)
Ki-67 intermediate expression (14% to 19%)
and PgR high expression (≥20%)
Luminal B
(HER2-negative)
“Luminal B–like (HER2-negative)”
All of:
ER-positive
HER2-negative
And at least one of:
Ki-67 intermediate expression (14% to -19) and
PgR negative or low expression (<20%)
Ki-67 high expression (≥20%)
aER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; PgR,
Progesterone receptor.
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is, those classified as having luminal B–like in both sets of
definitions), the DDFS durations of the 2,722 women with
high PgR levels were significantly better than those of the
remaining 1,248 women with low PgR levels as assessed in
univariate analysis (P = 0.04 by Gray test), but the associ-
ation disappeared in the multivariable analysis (HR = 1.01,
95% CI = 0.85 to 1.20, P = 0.88) (Figure 2c).
The cumulative incidence of distant metastasis (or breast
cancer–related death as a first event) was evenly low for
women with low Ki-67 expression and high PgR levels
(3.9%), for women with low Ki-67 expression and low PgR
levels (4.9%) and for women with intermediate Ki-67 ex-
pression and high PgR levels (8.1%). In contrast, it was
evenly high for women with intermediate Ki-67 expression
and low PgR levels (15.5%), for women with high Ki-
67 expression and high PgR levels (16.7%) and for women
with high Ki-67 expression and low PgR levels (18.5%)
(Figure 2d).
Multivariate analysis confirmed statistically significant
increased risks of distant metastasis for women with
intermediate Ki-67 expression and low PgR levels (HR =
2.36, 95% CI = 1.67 to 3.34, P < 0.0001), for women with
high Ki-67 expression and high PgR levels (HR = 1.93,
95% CI = 1.45 to 2.58, P < 0.0001) and for women with
high Ki-67 expression and low PgR levels (HR = 1.96, 95%
CI = 1.44 to 2.67, P < 0.0001) compared to women with
low Ki-67 expression and high PgR levels. No significant
increased risk of distant metastasis was observed
for women with low Ki-67 expression and low PgR
levels (HR = 1.05, 95% CI = 0.67 to 1.65, P = 0.81) and
for women with intermediate Ki-67 expression and high
PgR levels (HR = 1.27, 95% CI = 0.93 to 1.75, P = 0.14),
again, compared to women with low Ki-67 expression
and high PgR levels (Figure 2e).
Proposal for new definitions of intrinsic molecular subtypes
On the basis of our findings, we propose new definitions
of the luminal intrinsic molecular subtypes which would
better stratify patients in terms of DDFS. We would clas-
sify the two subtypes as follows. (1) Luminal A–like tu-
mors are ER-positive and HER2-negative with low Ki-67
expression (<14%) or with intermediate Ki-67 expression
(14% to 19%) and high PgR levels (≥20%). (2) Luminal
B–like (HER2-negative) tumors are ER-positive and HER2-
negative with intermediate Ki-67 expression (14% to 19%)
and low PgR levels (<20%) or with high Ki-67 expression
(≥20%) (Table 2).
As a result, 4,890 women (51.9%) were considered to
have luminal A–like and 4,525 (48.1%) to have luminal
B–like breast cancer (Additional file 1: Table S3). The
cumulative incidence of distant metastasis at 10 years
was 5.5% for luminal A–like and 17.1% for luminal B–like
breast cancer (Figure 3). After adjustment for potentialconfounders, the risk (HR) of distant disease for women
with luminal B–like versus luminal A–like tumors was
1.75 (95% CI = 1.46 to 2.11, P < 0.0001).
According to our proposed new definitions, the majo-
rity of luminal A–like tumors in our series were either
well-differentiated (41.7%) or moderately differentiated
(55.7%), and relatively few were poorly differentiated
(2.5%). In contrast, the majority of the luminal B–like
tumors were either moderately differentiated (52.6%) or
poorly differentiated (42.8%), and relatively few were well-
differentiated (4.6%) (Figure 4). The outcomes of the
patients with poorly differentiated luminal A–like tumors
were not significantly different from those of patients with
poorly differentiated luminal B–like tumors. Reciprocally,
the outcomes of the few patients with well-differentiated
luminal B–like tumors were significantly better than those
of patients with moderately or poorly differentiated luminal
B–like tumors, but significantly worse than those of
women with well-differentiated luminal A–like tumors.
Discussion
We extrapolated data from a large monoinstitutional
series of patients who had undergone surgery for breast
cancer to assess the validity and clinical impact, in terms
of DDFS, of the modified surrogate updated definitions
of the “luminal A” and “luminal B (HER2-negative)”
intrinsic molecular subtypes of breast cancer outlined in
the 2011 and 2013 versions of the St Gallen International
Figure 3 Distant disease-free survival according to our
proposed intrinsic molecular subtypes. Hazards ratios (HRs) and
95% confidence intervals (CIs) were calculated using a multivariable
Cox proportional hazards regression model adjusted for pathologic
tumor stage, pathologic node stage, tumor grade, peritumoral
vascular invasion and menopausal status.
Figure 4 Distant disease-free survival according to our proposed new
Hazard ratios and 95% confidence intervals (CIs) were calculated using a m
pathologic tumor stage, pathologic node stage, tumor grade, peritumoral v
between tumor grade and new intrinsic molecular subtype. The percentag
chemotherapy were 9.5% (G1), 24.73% (G2) and 42.0% (G3). Similarly, 21.3%
breast cancer, respectively, received adjuvant chemotherapy.
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Cancer guidelines [1,3].
The first change made by the panel was the require-
ment for substantial PgR positivity (≥20%) in the defi-
nition of luminal A–like disease. We found that (1) 854
(26.9%) of the 3,169 women in our series previously clas-
sified as having luminal A–like breast cancer (using the
threshold value <14% Ki-67 expression) would have been
reclassified as having luminal B–like breast cancer and,
consequently, (2) most should have been treated with
cytotoxic drugs. However, the majority of these 854
patients had well-differentiated or moderately differenti-
ated tumors, did not receive adjuvant chemotherapy and
nevertheless experienced similar favorable outcomes
compared to patients with tumors with low Ki-67 levels
and substantial PgR positivity.
The second modification was the selection, by the ma-
jority of the panel experts, of 20% as the threshold value
for Ki-67 for the distinction of luminal A and luminal B
intrinsic subtypes. We found that 1,721 (75.6%) of the
2,276 patients with tumors with intermediate Ki-67 ex-
pression (that is, comprising patients meeting the old and
new thresholds) had substantial PgR positivity (≥20%) and
had outcomes similar to those of patients with luminal A–
like breast cancer, thus confirming the correct classifica-
tion of this subgroup of patients. We also found that
the 555 patients with tumors with intermediate Ki-67definitions of intrinsic molecular subtypes and tumor grades.
ultivariable Cox proportional hazards regression model adjusted for
ascular invasion and menopausal status. P = 0.33 for the interaction
es of patients with luminal A–like breast cancer who received adjuvant
, 38.7% and 60.5% of patients with G1, G2 and G3, luminal B–like
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outcomes similar to those of patients with luminal B–like
breast cancer. These two observations support the
requirement for substantial PgR positivity (≥20%) in the
definition of luminal A–like disease among patients with
intermediate Ki-67 expression levels (14% to 19%).
Therefore, on the basis of our analysis, we propose
new clinicopathological definitions using 20% as a thres-
hold for Ki-67 to distinguish the luminal A and luminal
B intrinsic molecular breast cancer subtypes. In addition,
we propose a requirement for substantial PgR positivity
in the definition of luminal A–like disease only when
Ki-67 expression is between 14% and 20% (Table 2). Al-
though we found that luminal A–like tumors represented
only 33.7% and 42.9% of all ER-positive, HER2-negative
breast cancers when we applied the 2011 and 2013 St
Gallen surrogate definitions, respectively, they would rep-
resent about 50% of HER2-negative luminal tumors in
breast cancer patients according to our proposed new
definitions. This proportion is much the same as that ob-
served by study researchers who have defined intrinsic
molecular subtypes by utilizing gene expression profiling
[7,8]. The major implication of our proposed new distinc-
tion between luminal A–like tumors (more endocrine-
sensitive, more indolent and better prognosis) and luminal
B–like tumors (less endocrine-sensitive, more aggressive
and worse prognosis) is the impact on decision-making
regarding the utility or futility of adjuvant cytotoxic
therapy between these two groups.
Further evidence has accrued in the past several years
to support the use of multigene signatures to make dis-
tinctions between patients with different luminal disease
subtypes. Many different multigene assays provide prog-
nostic information, primarily derived from the sampling
of proliferation genes, which emphasizes the need for
some measure of proliferation in any surrogate classifi-
cation [9]. In many settings, however, patients can access
multigene testing only by making large personal out-of-
pocket payments. Therefore, from a global perspective,
multigene testing will remain inaccessible in the imme-
diate future for the majority of women with early breast
cancer. It is for these women that the 2013 St Gallen
Panel believed that the approach adopted, based on the
available clinicopathological testing and now expressed
in our proposed immunohistochemistry-based surrogate
classification scheme, will be more widely applicable at
lesser cost, notwithstanding its limited validation. Our
data confirm the clinical validity of our proposed classifi-
cation definitions. Despite being increased in number by
our proposal, only a small proportion of luminal A–like
tumors were defined as poorly differentiated (2.5%).
Reciprocally, a small proportion of our redefined lu-
minal B–like tumors were well-differentiated (4.6%).
Such a pattern was observed in a previous study inwhich the intrinsic subtype assignment was based on
gene expression profiling. Bastien et al. reported 14.1%
poorly differentiated luminal A tumors and 9.4% well-
differentiated luminal B tumors among women with locally
advanced primary invasive breast cancer studied using the
PAM50 gene set [8]. Interestingly, an accurate assessment
of tumor grade remains a powerful prognostic parameter,
though it is not included in any of the surrogate definitions
for luminal tumors. In our present series, patients with G1
tumors belonging to the luminal B class had significantly
better outcomes than patients with G2 and G3 tumors of
the same class, despite the fact that almost 80% of the
former group of patients did not receive any chemotherapy
in addition to endocrine therapy. Conversely, patients with
G3 tumors of the luminal A class had worse outcomes than
those with G1 and G2 tumors of the same class, with HRs
not different from the HR for patients with G3 tumors of
the luminal B class, despite the fact that >40% of the former
patient group did receive adjuvant chemotherapy. It is
tempting to speculate that a more comprehensive surrogate
definition of the luminal classes of tumors for clinical pur-
poses could incorporate grade as a first discriminator (G1
for luminal A and G3 for luminal B) and biological features
to define the luminal classes among the G2 tumors only.
However, the aim of our present study was to verify the
suitability of the surrogate definitions of luminal subtypes
according to the original parameters proposed by the St
Gallen international expert panel.
Strengths of the study
This study is based on our analysis of a large monoinsti-
tutional series of patients treated for breast cancer in a
high-volume reference center where treatment and man-
agement are widely standardized. All cases had been dis-
cussed individually after surgery by a multidisciplinary
team, and all decisions about adjuvant treatment had
been made, before the publication of the first St Gallen
clinicopathological surrogate definitions. Another impor-
tant strength is the central pathological examination of
all tumor specimens by a dedicated team of highly expe-
rienced pathologists, thus guaranteeing maximal reliabi-
lity and reproducibility of the evaluation of molecular
tumor characteristics. This is particularly important be-
cause interlaboratory variations in the evaluation of ER,
PgR and Ki-67 expression levels can impact the molecu-
lar classification of breast cancer when based on fixed
threshold values [10-12].
Study caveats
This is a retrospective study in which patients were trea-
ted according to well-defined protocols, but before the
dissemination of the definitions set forth in the St Gallen
guidelines. Therefore, some patients that we propose to
classify as having luminal A–like breast cancer, and for
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recommended, might have actually received and benefited
from adjuvant chemotherapy. Still, only a small proportion
(18.5%) of women with luminal A–like breast cancer re-
ceived adjuvant chemotherapy, in contrast to almost half
(46.9%) of women with luminal B–like breast cancer. We
also repeated all of our multivariable analyses, adjusting
for the use of adjuvant chemotherapy, and the results
remained virtually unchanged (Additional file 1: Table S2).
Another limitation of this study lies in the substantial
variability in Ki-67 scoring that has been observed even
at some of the world’s most experienced pathological
laboratories [11]. In the absence of standardization of
the scoring methodology for Ki-67 expression, which is
required for using fixed Ki-67 values and cutoffs in
clinical decision-making, it is the responsibility of each
local laboratory to decide on the Ki-67 thresholds that
best apply to their data.Conclusions
On the basis of the observed outcomes in a large series
of women treated for breast cancer, we propose an up-
dated definition of intrinsic molecular subtypes that may
maximize the number of patients classifiable as having
luminal A–like breast cancer for whom the use of cyto-
toxic drugs could largely be avoided. The derived num-
bers, characteristics and outcomes of patients with the
luminal A–like and luminal B–like subtypes under our
proposed definitions would be comparable to those
observed in studies in which researchers have defined
intrinsic molecular subtypes by utilizing gene expression
profiling.Additional file
Additional file 1: Table S1. Characteristics of the patients according to
Ki-67 and PgR expression levels. Table S2. Multivariate analysis for distant
disease-free survival. Table S3. Characteristics of the patients according
to our new proposal for molecular subtype definitions based on outcomes.Abbreviations
CI: Confidence interval; DDFS: Distant disease-free survival; ER: Estrogen
receptor; HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio;
IEO: European Institute of Oncology; PgR: Progesterone receptor; PVI:
Peritumoral vascular invasion.
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